Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Paula M O' Connor"'
Publikováno v:
PLoS ONE, Vol 8, Iss 3, p e58530 (2013)
It is becoming increasingly apparent that innovations from the "golden age" of antibiotics are becoming ineffective, resulting in a pressing need for novel therapeutics. The bacteriocin family of antimicrobial peptides has attracted much attention in
Externí odkaz:
https://doaj.org/article/8a176b389f4349b0adac4de721f442ed
Publikováno v:
Scientific Reports, Vol 8, Iss 1, Pp 1-8 (2018)
Abstract Bactofencin A is a novel class IId bacteriocin, produced by the intestinal isolate Lactobacillus salivarius DPC6502, which has potent activity against medically significant pathogens including Staphylococcus aureus. This bacteriocin is unusu
Externí odkaz:
https://doaj.org/article/c88d2e5ef0df477290231ea0360b64e8
Autor:
Lorraine A. Draper, Colin Hill, R. Paul Ross, Aoife Grainger, Paula M. O’ Connor, Des Field, Michelle O’ Connor
Publikováno v:
Appl Environ Microbiol
Nisin A is a potent antimicrobial with potential as an alternative to traditional antibiotics, and a number of genetically modified variants have been created that target clinically relevant pathogens. In addition to antimicrobial activity, nisin aut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24544291bd985cbbff4b18c8227db60f
https://hdl.handle.net/10468/12183
https://hdl.handle.net/10468/12183
Autor:
Beatriz Mesa-Pereira, Taís M. Kuniyoshi, Sara Arbulu, Collin Hill, Paul Ross, Ricardo Pinheiro de Souza Oliveira, Paula M. O’ Connor, Paul D. Cotter
Publikováno v:
Access Microbiology. 1
Pediocin PA −1 is class IIa bacteriocin that displays efficient antimicrobial activity against pathogenic Listeriaspp. This bacteriocin is known to lose activity during long periods of storage especially at non optimal pH, thus reducing its usefuln
Autor:
Colin Hill, Des Field, R. Paul Ross, Paul D. Cotter, Tony Blake, Paula M. O’ Connor, Harsh Mathur
Publikováno v:
Molecular Microbiology.
The emergence and dissemination of antibiotic resistant bacteria is a major medical challenge. Lantibiotics are highly modified bacterially produced antimicrobial peptides that have attracted considerable interest as alternatives or adjuncts to exist
Publikováno v:
Scientific Reports
Scientific Reports, Vol 8, Iss 1, Pp 1-8 (2018)
Scientific Reports, Vol 8, Iss 1, Pp 1-8 (2018)
Bactofencin A is a novel class IId bacteriocin, produced by the intestinal isolate Lactobacillus salivarius DPC6502, which has potent activity against medically significant pathogens including Staphylococcus aureus. This bacteriocin is unusual in tha
Autor:
Colin Hill, Paul D. Cotter, Catalin Iancu, Paula M. O’ Connor, Lorraine A. Draper, R. Paul Ross, Evelyn M. Molloy, Des Field
Publikováno v:
Microbial Biotechnology. 6:564-575
The lantibiotic lacticin 3147 consists of two ribosomally synthesized and post-translationally modified antimicrobial peptides, Ltnα and Ltnβ, which act synergistically against a wide range of Gram-positive microorganisms. We performed saturation m
Autor:
Colin Hill, Eileen F. O’ Shea, Emma J. Raftis, Paul D. Cotter, Paula M. O’ Connor, Catherine Stanton, R. Paul Ross, Paul W. O' Toole
Publikováno v:
CIÊNCIAVITAE
ResearcherID
ResearcherID
peer-reviewed Addendum to: O’Shea EF, O’Connor PM, Raftis EJ, O’Toole PW, Stanton C, Cotter PD, Ross RP, et al. Production of multiple bacteriocins from a single locus by gastrointestinal strains of Lactobacillus salivarius. J Bacteriol 2011; 1
Autor:
Paula M. O’ Connor, John F. Cryan, R. Paul Ross, Liam McAllan, Kanishka N. Nilaweera, Gerald F. Fitzgerald, Helen M. Roche, Paul D. Cotter, Peter Skuse
Publikováno v:
PLoS ONE, Vol 9, Iss 2, p e88904 (2014)
PLoS ONE
PLoS ONE
peer-reviewed Macronutrient quality and composition are important determinants of energy balance and the gut microbiota. Here, we investigated how changes to protein quality (casein versus whey protein isolate; WPI) and the protein to carbohydrate (P
Publikováno v:
PLoS ONE
PLoS ONE, Vol 8, Iss 3, p e58530 (2013)
PLoS ONE, Vol 8, Iss 3, p e58530 (2013)
peer-reviewed It is becoming increasingly apparent that innovations from the “golden age” of antibiotics are becoming ineffective, resulting in a pressing need for novel therapeutics. The bacteriocin family of antimicrobial peptides has attracted